3C-Like Proteinase from SARS Coronavirus Catalyzes Substrate

Total Page:16

File Type:pdf, Size:1020Kb

3C-Like Proteinase from SARS Coronavirus Catalyzes Substrate 4568 Biochemistry 2004, 43, 4568-4574 3C-like Proteinase from SARS Coronavirus Catalyzes Substrate Hydrolysis by a General Base Mechanism† Changkang Huang,‡ Ping Wei,‡ Keqiang Fan,‡ Ying Liu,‡ and Luhua Lai*,‡,§ State Key Laboratory for Structural Chemistry of Unstable and Stable Species, College of Chemistry and Molecular Engineering, and Center for Theoretical Biology, Peking UniVersity, Beijing 100871, China ReceiVed NoVember 11, 2003; ReVised Manuscript ReceiVed January 26, 2004 ABSTRACT: SARS 3C-like proteinase has been proposed to be a key enzyme for drug design against SARS. Lack of a suitable assay has been a major hindrance for enzyme kinetic studies and a large-scale inhibitor screen for SARS 3CL proteinase. Since SARS 3CL proteinase belongs to the cysteine protease family (family C3 in clan CB) with a chymotrypsin fold, it is important to understand the catalytic mechanism of SARS 3CL proteinase to determine whether the proteolysis proceeds through a general base catalysis mechanism like chymotrypsin or an ion pair mechanism like papain. We have established a continuous colorimetric assay for SARS 3CL proteinase and applied it to study the enzyme catalytic mechanism. The proposed catalytic residues His41 and Cys145 were confirmed to be critical for catalysis by mutating to Ala, while the Cys145 to Ser mutation resulted in an active enzyme with a 40-fold lower activity. From the pH dependency of catalytic activity, the pKa’s for His41 and Cys145 in the wild-type enzyme were estimated to be 6.38 and 8.34, while the pKa’s for His41 and Ser145 in the C145S mutant were estimated to be 6.15 and 9.09, respectively. The C145S mutant has a normal isotope effect in D2O for general base catalysis, that is, reacts slower in D2O, while the wild-type enzyme shows an inverse isotope effect which may come from the lower activation enthalpy. The pKa values measured for the active site residues and the activity of the C145S mutant are consistent with a general base catalysis mechanism and cannot be explained by a thiolate-imidazolium ion pair model. A novel form of coronavirus has been attributed as the Homology modeling for the SARS 3CL proteinase has been major cause of severe acute respiratory syndrome (SARS) performed by various groups (5-7), and the conformational that broke out in early 2003 (1, 2). The genome of SARS flexibility of the substrate binding site has been studied (7). coronavirus has been sequenced within a short period of time Virtual screening of small molecule libraries has predicted after isolation of the virus (3, 4). Coronaviruses are members possible inhibitors (6). An 8-mer peptide has been docked of positive-stranded RNA viruses featuring the largest viral on the model of SARS 3CL proteinase to study the RNA genomes known to date. Translation of the SARS interaction of SARS 3CL with its substrates (8). coronavirus replicase gene produces two proteins with Two crystal structures of coronavirus 3CL proteinase from overlapping sequences, polyproteins 1a (∼450 kDa) and 1ab transmissible gastroenteritis virus (TGEV) (9) and human (∼750 kDa), which are conserved both in length and in coronavirus (hCoV) 229E have been reported (5). Recently, amino acid sequence to other coronavirus replicase proteins. the crystal structure of SARS coronavirus 3CL proteinase Polyproteins 1a and 1ab are cleaved by the internally encoded has also been solved by two groups, with the coordinates 3C-like proteinase (3CL) to release functional proteins deposited in the Protein Data Bank (http://www.rcsb.org). necessary for virus replication. SARS 3CL1 proteinase is fully In addition, Z. H. Rao’s group also elucidated the complex conserved among all released SARS coronavirus genome structure of SARS 3CL proteinase with a covalent bonded sequences and is highly homologous with other coronavirus substrate analogue, which provided insights on the substrate 3CL proteinases. Due to its functional importance in the viral binding site (10). All of the reported structures of coronavirus life cycle, SARS 3CL proteinase has been proposed to be a 3CL proteinases are similar. The first two domains form a key target for structure-based drug design against SARS (5). chymotrypsin fold which is responsible for the catalytic reaction, and the third domain is R helical with unclear † This work was supported by the 863 High-Technology Project, the National Basic Research Project (2003CB715900), and NSFC biological function. Coronavirus 3CL proteinase shares the (10345004, 90103029, 20173001, 20228306). chymotrypsin fold with the 3C proteinases from other viruses * Corresponding author. Tel: +86 10 62757486. Fax: +86 10 such as rhinovirus, picornavirus, and hepatitis A virus (11- 62751725. E-mail: [email protected]. 13). The 3C proteinase of rhinovirus has been targeted to ‡ State Key Laboratory for Structural Chemistry of Unstable and - Stable Species, College of Chemistry and Molecular Engineering, develop drugs against the common cold (14 20). Peking University. As 3C proteinases and the catalytic domain in 3CL § Center for Theoretical Biology, Peking University. 1 proteinases are all cysteine proteinases with a chymotrypsin Abbreviations: SARS 3CL, SARS coronavirus 3C-like proteinase; - CD, circular dichroism; BME, 2′-mercaptoethanol; DTT, 1,4-dithio- fold, it is interesting to know whether they follow a thiolate threitol. imidazolium ion pair catalytic mechanism as found with 10.1021/bi036022q CCC: $27.50 © 2004 American Chemical Society Published on Web 03/12/2004 General Base Catalysis by SARS 3CL Proteinase Biochemistry, Vol. 43, No. 15, 2004 4569 Table 1: Primers Used to Generate SARS 3CL Proteinase Mutants mutants sequence H41A sense primer: 5′-CAGTATACTGTCCAAGAGCAGTCATTTGCACAGCAGAAGAC-3′ antisense primer: 5′-GTCTTCTGCTGTGCAAATGACTGCTCTTGGACAGTATACTG-3′ C145A sense primer: 5′-CTTTCCTTAATGGATCAGCAGGTAGTGTTGGTTTTAAC-3′ antisense primer: 5′-GTTAAAACCAACACTACCTGCTGATCCATTAAGGAAAG-3′ C145S sense primer: 5′-CTTTCCTTAATGGATCATCTGGTAGTGTTGGTTTTAAC-3′ antisense primer: 5′-GTTAAAACCAACACTACCAGATGATCCATTAAGGAAAG-3′ papain (21-24). It was recently shown that 3C proteinases eluted with another 180 mL of buffer C. The purity of each from picornain virus, poliovirus, and sortase from Staphyl- mutant was verified by SDS-PAGE. Secondary and tertiary ococcus aureus do not contain a thiolate-imidazolium ion structures of the mutants were determined to be essentially pair in their active site (25-27). Compared to the catalytic the same as the wild-type enzyme (data not shown) as triad in 3C proteinase, only two catalytic residues were found monitored by far- and near-UV CD. in 3CL proteinases of coronaviruses (5, 9, 28). Whether 3CL Construction of Plasmid pET 3CLP-21h, Protein Expres- proteinase of coronavirus follows an ion pair mechanism or sion, and Purification. The non-His-tagged SARS 3C-like a general base catalytic mechanism is important to understand proteinase was amplified by PCR from the plasmid pET the kinetic mechanism and to carry out structural and/or 3CLP-21x using primers 3CLP-Nhe (5′-CACTGCTAGCG- mechanism-based drug design. On the basis of our previous GTTTTAGGAAAATGGCATTCCC-3′) and 3CLP-Hind(5′- study on the cloning, expression, and substrate specificity CCTCAAGCTTATTGGAAGGTAACACCAGAGC-3′). The of SARS 3CL proteinase (29), we have established a colorimetric assay using a synthetic substrate for SARS 3CL PCR product was inserted into the NheI and HindIII sites of proteinase and characterized its enzyme catalysis mechanism. pET21a DNA. The resulting plasmid pET 3CLP-21h was While His41 and Cys145 were confirmed to be crucial for transformed into E. coli BL21(DE3) cells for expression. The catalysis by mutating to Ala, the substitution of Cys145 with recombinant 3CLP-21h was purified by fractional precipita- Ser resulted in an active enzyme. From pH-dependent tion with ammonium sulfate and further purified by using an anion-exchange column, HiTrap Q HP (Amersham catalytic activities, the calculated pKa values for His41 and Cys145 in the wild-type enzyme and for His41 and Ser145 Bioscience), and a gel filtration column, Sephacryl S-200 in the C145S mutant indicated that the enzyme catalysis HR (Amersham Bioscience). follows a general base catalysis mechanism and does not Substrate Specificity of C145S. Three substrate peptides contain a thiolate-imidazolium ion pair in its active site. derived from the natural cleavage sites of the SARS-CoV polyprotein were used in this study and were synthesized as EXPERIMENTAL PROCEDURES previously described (29). Their sequences are listed in Table Site-Directed Mutagenesis of SARS-CoV 3CL Proteinase. 3. The SARS 3CL proteinase C145S mutant was incubated The construction of the plasmid pET 3CLP-21x and the with different substrates in 40 mM Tris-HCl buffer, pH 7.3, expression and purification of the C-terminal His-tagged with a final enzyme concentration of 76.9 µM. The concen- SARS-CoV 3CL proteinase have been reported previously trations of substrate peptides were 0.4 mM for S01 and S06 (29). The H41A, C145A, C145S mutants in SARS-CoV 3CL and 0.2 mM for S09. The reaction mixture was analyzed by proteinase were prepared with the QuikChange site-directed RP-HPLC using a 15 min, 0-50% linear gradient of mutagenesis kit (Stratagene) using pET 3CLP-21x as a acetonitrile with 0.1% trifluoroacetic acid after 25 h. kcat/Km template. The nucleotide sequences of primers used for site- was calculated using the equation: directed mutagenesis are listed in Table 1. The mutations ) - were verified by sequencing. The 3CL proteinase mutants ln PA ln PA0 kcatCEt/Km (1) were expressed in Escherichia coli, purified, and analyzed using a similar procedure for the wild-type protein (29). where PA was the peak area of the substrate peptide in the Briefly, appropriate plasmids were transformed into E. coli reacting mixture after 25 h, PA0 was the origin peak area of BL21(DE3) cells. Cultures were grown at 37 °Cin1Lof the substrate peptide, and CE was the total concentration of LB containing ampicillin (100 µg/mL) until the OD at 600 3C-like proteinase. nm reached 0.8 and induced with 0.5 mM IPTG at 30 °C for 3 h.
Recommended publications
  • Cysteine Proteinases of Microorganisms and Viruses
    ISSN 00062979, Biochemistry (Moscow), 2008, Vol. 73, No. 1, pp. 113. © Pleiades Publishing, Ltd., 2008. Original Russian Text © G. N. Rudenskaya, D. V. Pupov, 2008, published in Biokhimiya, 2008, Vol. 73, No. 1, pp. 317. REVIEW Cysteine Proteinases of Microorganisms and Viruses G. N. Rudenskaya1* and D. V. Pupov2 1Faculty of Chemistry and 2Faculty of Biology, Lomonosov Moscow State University, 119991 Moscow, Russia; fax: (495) 9393181; Email: [email protected] Received May 7, 2007 Revision received July 18, 2007 Abstract—This review considers properties of secreted cysteine proteinases of protozoa, bacteria, and viruses and presents information on the contemporary taxonomy of cysteine proteinases. Literature data on the structure and physicochemical and enzymatic properties of these enzymes are reviewed. High interest in cysteine proteinases is explained by the discovery of these enzymes mostly in pathogenic organisms. The role of the proteinases in pathogenesis of several severe diseases of human and animals is discussed. DOI: 10.1134/S000629790801001X Key words: cysteine proteinases, properties, protozoa, bacteria, viruses Classification and Catalytic Mechanism papain and related peptidases showed that the catalytic of Cysteine Proteinases residues are arranged in the following order in the polypeptide chain: Cys, His, and Asn. Also, a glutamine Cysteine proteinases are peptidyl hydrolases in residue preceding the catalytic cysteine is also important which the role of the nucleophilic group of the active site for catalysis. This residue is probably involved in the for is performed by the sulfhydryl group of a cysteine residue. mation of the oxyanion cavity of the enzyme. The cat Cysteine proteinases were first discovered and investigat alytic cysteine residue is usually followed by a residue of ed in tropic plants.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • SVM and a Novel POOL Method Coupled with THEMATICS For
    SVM and a Novel POOL Method Coupled with THEMATICS for Protein Active Site Prediction A DISSERTATION SUBMITTED TO THE COLLEGE OF COMPUTER AND INFORMATION SCIENCE OF NORTHEASTERN UNIVERSITY IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY By Wenxu Tong April 2008 ©Wenxu Tong, 2008 ALL RIGHTS RESERVED Acknowledgements I have a lot of people to thank. I am mostly indebted to my advisor Dr. Ron Williams. He generously allowed me to work on a problem with the idea he developed decades ago and guided me through the research to turn it from just a mere idea into a useful system to solve important problems. Without his kindness, wisdom and persistence, there would be no this dissertation. Another person I am so fortunate to meet and work with is Dr. Mary Jo Ondrechen, my co-advisor. It was her who developed the THEMATICS method, which this dissertation works on. Her guidance and help during my research is critical for me. I am grateful to all the committee members for reading and commenting my dissertation. Especially, I am thankful to Dr. Jay Aslam, who provided a lot of advice for my research, and Dr. Bob Futrelle, who brought me into the field and provided much help in my writing of this dissertation. I also thank Dr. Budil for the time he spent serving as my committee member, especially during all the difficulties and inconvenience he happened to experience unfortunately during the time. I am so fortunate to work in the THEMATICS group with Dr. Leo Murga, Dr.
    [Show full text]
  • Families and Clans of Cysteine Peptidases
    Families and clans of eysteine peptidases Alan J. Barrett* and Neil D. Rawlings Peptidase Laboratory. Department of Immunology, The Babraham Institute, Cambridge CB2 4AT,, UK. Summary The known cysteine peptidases have been classified into 35 sequence families. We argue that these have arisen from at least five separate evolutionary origins, each of which is represented by a set of one or more modern-day families, termed a clan. Clan CA is the largest, containing the papain family, C1, and others with the Cys/His catalytic dyad. Clan CB (His/Cys dyad) contains enzymes from RNA viruses that are distantly related to chymotrypsin. The peptidases of clan CC are also from RNA viruses, but have papain-like Cys/His catalytic sites. Clans CD and CE contain only one family each, those of interleukin-ll3-converting enz3wne and adenovirus L3 proteinase, respectively. A few families cannot yet be assigned to clans. In view of the number of separate origins of enzymes of this type, one should be cautious in generalising about the catalytic mechanisms and other properties of cysteine peptidases as a whole. In contrast, it may be safer to gener- alise for enzymes within a single family or clan. Introduction Peptidases in which the thiol group of a cysteine residue serves as the nucleophile in catalysis are defined as cysteine peptidases. In all the cysteine peptidases discovered so far, the activity depends upon a catalytic dyad, the second member of which is a histidine residue acting as a general base. The majority of cysteine peptidases are endopeptidases, but some act additionally or exclusively as exopeptidases.
    [Show full text]
  • Peptide Sequence
    Peptide Sequence Annotation AADHDG CAS-L1 AAEAISDA M10.005-stromelysin 1 (MMP-3) AAEHDG CAS-L2 AAEYGAEA A01.009-cathepsin D AAGAMFLE M10.007-stromelysin 3 (MMP-11) AAQNASMW A06.001-nodavirus endopeptidase AASGFASP M04.003-vibriolysin ADAHDG CAS-L3 ADAPKGGG M02.006-angiotensin-converting enzyme 2 ADATDG CAS-L5 ADAVMDNP A01.009-cathepsin D ADDPDG CAS-21 ADEPDG CAS-L11 ADETDG CAS-22 ADEVDG CAS-23 ADGKKPSS S01.233-plasmin AEALERMF A01.009-cathepsin D AEEQGVTD C03.007-rhinovirus picornain 3C AETFYVDG A02.001-HIV-1 retropepsin AETWYIDG A02.007-feline immunodeficiency virus retropepsin AFAHDG CAS-L24 AFATDG CAS-25 AFDHDG CAS-L26 AFDTDG CAS-27 AFEHDG CAS-28 AFETDG CAS-29 AFGHDG CAS-30 AFGTDG CAS-31 AFQHDG CAS-32 AFQTDG CAS-33 AFSHDG CAS-L34 AFSTDG CAS-35 AFTHDG CAS-L36 AGERGFFY Insulin B-chain AGLQRGGG M14.004-carboxypeptidase N AGSHLVEA Insulin B-chain AIDIDG CAS-L37 AIDPDG CAS-38 AIDTDG CAS-39 AIDVDG CAS-L40 AIEHDG CAS-L41 AIEIDG CAS-L42 AIENDG CAS-43 AIEPDG CAS-44 AIEQDG CAS-45 AIESDG CAS-46 AIETDG CAS-47 AIEVDG CAS-48 AIFQGPID C03.007-rhinovirus picornain 3C AIGHDG CAS-49 AIGNDG CAS-L50 AIGPDG CAS-L51 AIGQDG CAS-52 AIGSDG CAS-53 AIGTDG CAS-54 AIPMSIPP M10.051-serralysin AISHDG CAS-L55 AISNDG CAS-L56 AISPDG CAS-57 AISQDG CAS-58 AISSDG CAS-59 AISTDG CAS-L60 AKQRAKRD S08.071-furin AKRQGLPV C03.007-rhinovirus picornain 3C AKRRAKRD S08.071-furin AKRRTKRD S08.071-furin ALAALAKK M11.001-gametolysin ALDIDG CAS-L61 ALDPDG CAS-62 ALDTDG CAS-63 ALDVDG CAS-L64 ALEIDG CAS-L65 ALEPDG CAS-L66 ALETDG CAS-67 ALEVDG CAS-68 ALFQGPLQ C03.001-poliovirus-type picornain
    [Show full text]
  • Design, Synthesis and Analysis of FMDV 3C-Protease Inhibitors
    Design, Synthesis and Analysis of FMDV 3C-Protease Inhibitors by Núria Roqué-Rosell A thesis submitted to Imperial College London in candidature for the Diploma of Imperial College and for the degree of Doctor of Philosophy. Department of Chemistry Imperial College London Exhibition Road London, SW7 2AZ June 2008 Abstract Foot-and-mouth disease virus (FMDV) causes a highly infectious disease of cloven-hoofed livestock with economically devastating consequences. The political and technical problems associated with the use of FMDV vaccines make drug- based disease control an attractive alternative. The FMDV genome is translated as a single polypeptide precursor that is cleaved into functional proteins by virally- encoded proteases. Ten of the thirteen cleavages are performed by the highly conserved 3C protease (3Cpro), making this enzyme an attractive target for anti-viral drugs (Curry et al., 2007a). pro This thesis describes the design, synthesis and evaluation of FMDV 3C inhibitors. A study of the activity of different FMDV 3Cpro mutants and a recently determined enzyme–substrate crystal structure provide an insight to the structure– activity relationships of the target and provides a basis for the inhibitor design (Curry et al., 2007b; Sweeney et al., 2007). Taking the enzyme‘s specificity as a starting point (Birtley et al., 2005), a small peptide sequence corresponding to an optimal substrate has been modified at the C-terminus, by the addition of a warhead, making it able to irreversibly react with the active site of this cysteine protease. Several synthetic routes have been developed, one allowed easy modification of the peptidic component of the inhibitor, whereas a second was designed to enable the introduction of variation on the warhead moiety.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur Et Al
    US 2012026.6329A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur et al. (43) Pub. Date: Oct. 18, 2012 (54) NUCLEICACIDS AND PROTEINS AND CI2N 9/10 (2006.01) METHODS FOR MAKING AND USING THEMI CI2N 9/24 (2006.01) CI2N 9/02 (2006.01) (75) Inventors: Eric J. Mathur, Carlsbad, CA CI2N 9/06 (2006.01) (US); Cathy Chang, San Marcos, CI2P 2L/02 (2006.01) CA (US) CI2O I/04 (2006.01) CI2N 9/96 (2006.01) (73) Assignee: BP Corporation North America CI2N 5/82 (2006.01) Inc., Houston, TX (US) CI2N 15/53 (2006.01) CI2N IS/54 (2006.01) CI2N 15/57 2006.O1 (22) Filed: Feb. 20, 2012 CI2N IS/60 308: Related U.S. Application Data EN f :08: (62) Division of application No. 1 1/817,403, filed on May AOIH 5/00 (2006.01) 7, 2008, now Pat. No. 8,119,385, filed as application AOIH 5/10 (2006.01) No. PCT/US2006/007642 on Mar. 3, 2006. C07K I4/00 (2006.01) CI2N IS/II (2006.01) (60) Provisional application No. 60/658,984, filed on Mar. AOIH I/06 (2006.01) 4, 2005. CI2N 15/63 (2006.01) Publication Classification (52) U.S. Cl. ................... 800/293; 435/320.1; 435/252.3: 435/325; 435/254.11: 435/254.2:435/348; (51) Int. Cl. 435/419; 435/195; 435/196; 435/198: 435/233; CI2N 15/52 (2006.01) 435/201:435/232; 435/208; 435/227; 435/193; CI2N 15/85 (2006.01) 435/200; 435/189: 435/191: 435/69.1; 435/34; CI2N 5/86 (2006.01) 435/188:536/23.2; 435/468; 800/298; 800/320; CI2N 15/867 (2006.01) 800/317.2: 800/317.4: 800/320.3: 800/306; CI2N 5/864 (2006.01) 800/312 800/320.2: 800/317.3; 800/322; CI2N 5/8 (2006.01) 800/320.1; 530/350, 536/23.1: 800/278; 800/294 CI2N I/2 (2006.01) CI2N 5/10 (2006.01) (57) ABSTRACT CI2N L/15 (2006.01) CI2N I/19 (2006.01) The invention provides polypeptides, including enzymes, CI2N 9/14 (2006.01) structural proteins and binding proteins, polynucleotides CI2N 9/16 (2006.01) encoding these polypeptides, and methods of making and CI2N 9/20 (2006.01) using these polynucleotides and polypeptides.
    [Show full text]
  • All Enzymes in BRENDA™ the Comprehensive Enzyme Information System
    All enzymes in BRENDA™ The Comprehensive Enzyme Information System http://www.brenda-enzymes.org/index.php4?page=information/all_enzymes.php4 1.1.1.1 alcohol dehydrogenase 1.1.1.B1 D-arabitol-phosphate dehydrogenase 1.1.1.2 alcohol dehydrogenase (NADP+) 1.1.1.B3 (S)-specific secondary alcohol dehydrogenase 1.1.1.3 homoserine dehydrogenase 1.1.1.B4 (R)-specific secondary alcohol dehydrogenase 1.1.1.4 (R,R)-butanediol dehydrogenase 1.1.1.5 acetoin dehydrogenase 1.1.1.B5 NADP-retinol dehydrogenase 1.1.1.6 glycerol dehydrogenase 1.1.1.7 propanediol-phosphate dehydrogenase 1.1.1.8 glycerol-3-phosphate dehydrogenase (NAD+) 1.1.1.9 D-xylulose reductase 1.1.1.10 L-xylulose reductase 1.1.1.11 D-arabinitol 4-dehydrogenase 1.1.1.12 L-arabinitol 4-dehydrogenase 1.1.1.13 L-arabinitol 2-dehydrogenase 1.1.1.14 L-iditol 2-dehydrogenase 1.1.1.15 D-iditol 2-dehydrogenase 1.1.1.16 galactitol 2-dehydrogenase 1.1.1.17 mannitol-1-phosphate 5-dehydrogenase 1.1.1.18 inositol 2-dehydrogenase 1.1.1.19 glucuronate reductase 1.1.1.20 glucuronolactone reductase 1.1.1.21 aldehyde reductase 1.1.1.22 UDP-glucose 6-dehydrogenase 1.1.1.23 histidinol dehydrogenase 1.1.1.24 quinate dehydrogenase 1.1.1.25 shikimate dehydrogenase 1.1.1.26 glyoxylate reductase 1.1.1.27 L-lactate dehydrogenase 1.1.1.28 D-lactate dehydrogenase 1.1.1.29 glycerate dehydrogenase 1.1.1.30 3-hydroxybutyrate dehydrogenase 1.1.1.31 3-hydroxyisobutyrate dehydrogenase 1.1.1.32 mevaldate reductase 1.1.1.33 mevaldate reductase (NADPH) 1.1.1.34 hydroxymethylglutaryl-CoA reductase (NADPH) 1.1.1.35 3-hydroxyacyl-CoA
    [Show full text]
  • Papain-Like Proteases: Applications of Their Inhibitors
    African Journal of Biotechnology Vol. 6 (9), pp. 1077-1086, 2 May 2007 Available online at http://www.academicjournals.org/AJB ISSN 1684–5315 © 2007 Academic Journals Review Papain-like proteases: Applications of their inhibitors Vikash K. Dubey1*, Monu Pande2, Bishal Kumar Singh1 and Medicherla V. Jagannadham2 1Department of Biotechnology, Indian Institute of Technology, Guwahati- 781039, Assam, India. 2Molecular Biology Unit, Institute of Medical Sciences, Banaras Hindu University, Varanasi-221005, India. Accepted 5 February, 2007 Proteases are one of the most important classes of enzyme and expressed throughout the animal and plant kingdoms as well as in viruses and bacteria. The protease family has drawn special attention for drug target for cure of several diseases such as osteoporosis, arthritis and cancer. Many proteases from various sources are being studied extensively with respect to activity, inhibition and structure. In this review, we hope to bring together the information available about the proteases with particular emphasis on papain-like plant cysteine proteases. Besides, protease inhibitors and their potential utilities are also discussed. Key words: Proteases, plant latex, reaction mechanism and protease inhibitors. INTRODUCTION Proteolytic enzymes are of widespread interest because shows evidence of their evolutionary relationship by their of there industrial application and because they have similar tertiary structures, by the order of catalytic resid- been implicated in the design and synthesis of thera- ues in their sequences, or by common sequence motifs peutic agents (Neurath, 1989). With the advent of mole- around the catalytic residues. The proteases have been cular biology, proteolytic enzymes have become a fertile organized in to evolutionary families and clans by and exciting field of basic as well as applied research.
    [Show full text]
  • Miscellaneous Pesticides Articles February 2014
    Maine Board of Pesticides Control Miscellaneous Pesticides Articles February 2014 (identified by Google alerts or submitted by individuals) Are there alien genes in your food? - Maine news, sports, obituaries, weat... http://bangordailynews.com/2014/01/01/opinion/are-there-alien-genes-in... By Nancy Oden, Special to the BDN Posted Jan. 01, 2014, at 3:16 p.m. “Alien genes” are genes from one species that are forced into a different species, creating a mutant life form that would never occur in nature. They’re called genetically modified organisms, or GMOs, and are created by chemical and pharmaceutical corporations. They include, for example: — The bacterium Bacillus thuringiensis spliced into some potatoes and corn, causing the plants to produce a toxin to ward off insects; — Fish genes into tomatoes (a product that didn’t go on the market); — Genes from antibiotics and pesticides inserted into corn, soy, canola, sugar beets — in your food today, unless you’re eating organic. Creating GMOs is not selective breeding within one species. Selective breeding cross-pollinates, for example, one tomato with another, leading to a somewhat different tomato. This happens in nature all the time. It would never lead to a tomato with fish genes in it. Forcing potentially toxic material into the plants humans and animals eat is not meant to “improve” the plants; it’s meant to sell more product — such as agriculture giant Monsanto’s Roundup Ready soybeans, alfalfa, corn, cotton, canola and sugar beets, which contain tolerance to Roundup herbicides. Don’t wonder why the government allows these materials in your food: A former Monsanto executive is heading up the Food and Drug Administration.
    [Show full text]
  • WO 2015/021058 A2 12 February 2015 (12.02.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/021058 A2 12 February 2015 (12.02.2015) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, C12Q 1/37 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/US20 14/049805 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 5 August 2014 (05.08.2014) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/862,363 5 August 2013 (05.08.2013) US kind of regional protection available): ARIPO (BW, GH, 61/987,5 18 2 May 2014 (02.05.2014) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (71) Applicant: GREENLIGHT BIOSCIENCES, INC. TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, [US/US]; 200 Boston Avenue, Suite 3100, Medford, MA EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 02155 (US).
    [Show full text]
  • Supplementary Material (ESI) for Natural Product Reports
    Electronic Supplementary Material (ESI) for Natural Product Reports. This journal is © The Royal Society of Chemistry 2014 Supplement to the paper of Alexey A. Lagunin, Rajesh K. Goel, Dinesh Y. Gawande, Priynka Pahwa, Tatyana A. Gloriozova, Alexander V. Dmitriev, Sergey M. Ivanov, Anastassia V. Rudik, Varvara I. Konova, Pavel V. Pogodin, Dmitry S. Druzhilovsky and Vladimir V. Poroikov “Chemo- and bioinformatics resources for in silico drug discovery from medicinal plants beyond their traditional use: a critical review” Contents PASS (Prediction of Activity Spectra for Substances) Approach S-1 Table S1. The lists of 122 known therapeutic effects for 50 analyzed medicinal plants with accuracy of PASS prediction calculated by a leave-one-out cross-validation procedure during the training and number of active compounds in PASS training set S-6 Table S2. The lists of 3,345 mechanisms of action that were predicted by PASS and were used in this study with accuracy of PASS prediction calculated by a leave-one-out cross-validation procedure during the training and number of active compounds in PASS training set S-9 Table S3. Comparison of direct PASS prediction results of known effects for phytoconstituents of 50 TIM plants with prediction of known effects through “mechanism-effect” and “target-pathway- effect” relationships from PharmaExpert S-79 S-1 PASS (Prediction of Activity Spectra for Substances) Approach PASS provides simultaneous predictions of many types of biological activity (activity spectrum) based on the structure of drug-like compounds. The approach used in PASS is based on the suggestion that biological activity of any drug-like compound is a function of its structure.
    [Show full text]